In the fast-paced world of stock trading, pharmaceutical companies often emerge as some of the most lucrative investment options. With their potential for groundbreaking medical advancements, expanding global reach, and ever-increasing demand for healthcare products, pharma stocks have become a favorite among investors.
A small cap pharmaceutical Stock “Marksans Pharma” is grabbing investor attention.
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
The stock price surge 7 % during today’s trading session and closed at 81.05 with an eye-catching traded volume of 18.93 M which is almost 7.5X the average volume of 10 days.
Milestone
Since incorporation in 2001, Marksans Pharma has undergone various phases of transformation, consolidation, mergers and acquisitions. From its initial identity of being a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., the organization has grown from strength-to-strength to make a mark in the global pharmaceutical space.
2009 -Marksans Pharma established itself as a global player
2008 -Acquired Bells, Sons & Co. (Druggists) Ltd.
Acquired Relonchem Limited
2005 - Acquired Nova Pharmaceuticals Australasia Pty Ltd.
2003 - Spun-off into a separate entity - Glenmark Laboratories Ltd.
Changed its name to "Marksans Pharma Ltd"
2001 - Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.
Global Presence
In order to expand its global footprint and to consolidate its operations and product offerings, Marksans had entered into strategic tie-ups and acquired key players in the major global markets.
Some of our major activities include:
- Tie-ups with leading globalMNC’s for offering CRAMS
- Setting up of specialized andstate-of-the-art soft gel manufacturing facilities
- Entering into long-termout-licensing agreements with leading pharmaceutical companies
- Setting up our own front-endsacross major global markets
- Establishinga strong marketing presence in domestic markets
Financial Performance
Shareholding Pattern
FII has increased their stakes in March quarter by 10.88 %.
DII also increased their holding by 0.5 %
0 Comments